Azacitidine in a patient with myelodysplastic syndrome: Impact of switching from a 5-day to the approved 7-day dosing schedule

Subjects

Subjects :

Male
Antimetabolites, Antineoplastic
Cancer Research
Schedule
Pediatrics
medicine.medical_specialty
Time Factors
Antimetabolites
Azacitidine
Pharmacology
Drug Administration Schedule
Dose-Response Relationship
medicine
Drug approval
Humans
Dosing
Aged
Disease Progression
Dose-Response Relationship, Drug
Drug Approval
Myelodysplastic Syndromes
business.industry
Myelodysplastic syndromes
Disease progression
Hematology
medicine.disease
Antineoplastic
Settore MED/15 - MALATTIE DEL SANGUE
Oncology
Drug
business
medicine.drug

Details

ISSN :

01452126

Volume :

36

Database :

OpenAIRE

Journal :

Leukemia Research

Accession number :

edsair.doi.dedup.....e9592e2adbd400b5338750c9c787c46d

Full Text :

https://doi.org/10.1016/j.leukres.2011.08.010